Lincoln Pharmaceuticals' Q2 FY 2026-27 Quarterly Results

Result Summary

• Lincoln Pharmaceuticals Ltd reported a 0.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 17.7%.
• Its expenses for the quarter were up by 11.6% QoQ and 21.2% YoY.
• The net profit decreased 43.6% QoQ and increased 2.3% YoY.
• The earnings per share (EPS) of Lincoln Pharmaceuticals Ltd stood at 10.2 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Lincoln Pharmaceuticals Ltd is a company engaged primarily in the pharmaceutical industry. It specializes in the development, manufacturing, and marketing of a wide range of pharmaceutical products. These products typically include formulations across various therapeutic segments, catering to both domestic and international markets. As a player within the pharmaceutical sector, Lincoln Pharmaceuticals Ltd focuses on creating medicines that enhance the quality of life and contribute to healthcare improvements. Recent developments for the company may include expansions, product launches, or strategic partnerships, but specific information regarding these is not available in the provided data.

Revenue

In the second quarter of fiscal year 2027 (Q2FY27), Lincoln Pharmaceuticals Ltd reported total income of ₹200.88 crores. This represents a slight decrease of 0.3% when compared to the previous quarter (Q1FY27), where total income was ₹201.55 crores. However, on a year-over-year (YoY) basis, the company experienced a significant increase of 17.7% in total income from ₹170.60 crores in the second quarter of fiscal year 2026 (Q2FY26). This growth indicates an upward trend in revenue for the company over the past year, despite the minor decline from the previous quarter.

Profitability

The profitability metrics for Lincoln Pharmaceuticals Ltd in Q2FY27 exhibit a notable decline in comparison to the previous quarter. The profit before tax (PBT) for Q2FY27 stood at ₹29.02 crores, marking a decrease of 39.0% from ₹47.55 crores in Q1FY27. Despite this quarter-over-quarter (QoQ) decline, the year-over-year (YoY) change shows a modest increase of 0.7% compared to ₹28.81 crores in Q2FY26. Profit after tax (PAT) for Q2FY27 was ₹20.43 crores, a reduction of 43.6% from the previous quarter, which was ₹36.23 crores. The YoY comparison reveals a slight increase of 2.3% from ₹19.98 crores in Q2FY26. Earnings per share (EPS) also reflected these trends, decreasing by 43.6% QoQ to ₹10.20 in Q2FY27 from ₹18.09 in Q1FY27, with a YoY rise of 2.2% from ₹9.98 in Q2FY26.

Operating Metrics

The operating metrics for Lincoln Pharmaceuticals Ltd demonstrate a rise in total expenses, which were ₹171.86 crores in Q2FY27. This represents an 11.6% increase from ₹153.99 crores in Q1FY27 and a 21.2% rise from ₹141.79 crores in Q2FY26. The escalation in expenses contrasts with the company's revenue changes and has implications for the overall operating efficiency. The tax expense for Q2FY27 was ₹8.59 crores, which is lower than the previous quarter by 24.1%, when it was ₹11.32 crores, and also slightly decreased by 2.7% YoY from ₹8.83 crores in Q2FY26. These fluctuations in tax and expense levels can affect the company's net profit and overall financial performance.